Results 191 to 200 of about 79,496 (316)

Adrenal Insufficiency During Treatment With Immune‐Checkpoint Inhibitors: How to Simplify the Diagnostic Pathway?

open access: yesClinical Endocrinology, Volume 104, Issue 1, Page 39-46, January 2026.
ABSTRACT Objective and Background Early identification of adrenal insufficiency (AI) during immune‐checkpoint inhibitors (ICIs) is crucial to prevent life‐threatening consequences; however, the diagnosis is challenging. Design, Patients and Measurement In this prospective observational study, ICI‐treated cancer patients with morning serum cortisol (SC)
Alice Nervo   +6 more
wiley   +1 more source

Hypogonadotropic Hypogonadism

open access: yes, 2014
Adamowicz, Jan   +3 more
openaire   +2 more sources

Does Late-Onset Hypogonadism Occur by Aging? The Evaluation of IIEF, Ams-Q and Biochemical Parameters [PDF]

open access: hybrid, 2010
Oktay Üçer   +4 more
openalex   +1 more source

Sexual dysfunction care needs of gay, bisexual, and other men who have sex with men living with HIV in Montreal, Canada

open access: yesHIV Medicine, Volume 27, Issue 1, Page 74-85, January 2026.
Abstract Objectives Sexual dysfunction (SD) is common among gay, bisexual and other men who have sex with men (GBM) with HIV, yet little is known about their views on SD care. We explored these views to inform patient‐centred SD care to improve care delivery and sexual health outcomes.
Francesco Avallone   +6 more
wiley   +1 more source

Intersections of vitamin D deficiency, HIV and chronic liver diseases

open access: yesHIV Medicine, Volume 27, Issue 1, Page 4-17, January 2026.
Abstract Objectives Despite effective antiretroviral therapy (ART), chronic liver diseases remain a leading cause of morbidity and mortality among people with HIV, with metabolic dysfunction–associated steatotic liver disease (MASLD) now the predominant etiology. Vitamin D deficiency is also highly prevalent in this population.
Francesca Farina   +7 more
wiley   +1 more source

Is the Safety of Finasteride Correlated With Its Route of Administration: Topical Versus Oral? A Pharmacovigilance Study With Data From the United States Food and Drug Administration Adverse Event Reporting System

open access: yesInternational Journal of Dermatology, Volume 65, Issue 1, Page 108-118, January 2026.
ABSTRACT Background The United States Food and Drug Administration (FDA) approved oral finasteride for androgenetic alopecia. In 2022, approximately 2.6 million U.S. men used it for hair loss and prostate conditions. Post‐finasteride syndrome (PFS), proposed in 2012, involves persistent sexual and neuropsychiatric adverse events (AEs) after cessation ...
Aditya K. Gupta   +3 more
wiley   +1 more source

Hypogonadism and neurocognitive outcomes among childhood cancer survivors [PDF]

open access: green
Tomoko Yoshida   +11 more
openalex   +1 more source

Home - About - Disclaimer - Privacy